Figure 1: Western blotting for GFAP. (a) GFAP immunoblot of iNOS−/− control (Cont), cuprizone (CPZ), and cuprizone plus sildenafil (CPZ + Sild) groups. (b) β-actin immunoblot. (c) Graph represents quantification and statistical analysis. The control group showed basal expression of GFAP. CPZ treatment induced a significant increase of this protein and sildenafil plus CPZ did not reduce GFAP expression, which remained higher in relation to the control group. The experiment was performed in triplicate ( animals/group). The results were expressed as mean ± SE. * , ** compared to control.